Loading...
•
Jun 30, 2021
Dynavax Q2 2021 Earnings Report
Dynavax's financial performance for Q2 2021 was reported, featuring record HEPLISAV-B revenue and progress in CpG 1018 collaborations.
Key Takeaways
Dynavax reported a successful Q2 2021, marked by record HEPLISAV-B revenue of $13.7 million and significant CpG 1018 revenue of $39 million driven by multiple commercial supply agreements. The company achieved a net income of $4.5 million, a substantial improvement from the previous year's net loss.
Total revenue for the second quarter of 2021 was $52.8 million, a significant increase from $2.7 million in the same period of 2020.
HEPLISAV-B achieved its highest quarterly revenue to date at $13.7 million, driven by increased market share in targeted accounts.
CpG 1018 adjuvant generated $39.0 million in revenue during the quarter, supported by multiple commercial supply agreements with COVID-19 vaccine collaborators.
Net income for the second quarter of 2021 was $4.5 million, a significant turnaround from the net loss of $51.6 million in the second quarter of 2020.
Revenue by Segment
Forward Guidance
Dynavax anticipates several milestones, including a CDC vote on universal hepatitis B recommendation, data readouts from CpG 1018 COVID-19 collaboration partners, and data from the Tdap-1018 Phase 1 clinical trial.
Positive Outlook
- Potential for emergency or conditional use authorization of COVID-19 vaccines by the end of 2021.
- Expected vote on a universal hepatitis B recommendation for all previously unvaccinated adults in October.
- Data from Tdap-1018 in the ongoing Phase 1 clinical trial expected in the first quarter of 2022.
- Multiple data readouts from CpG 1018 COVID-19 collaboration partners.
- Continued progress in commercializing HEPLISAV-B.
Challenges Ahead
- Risks related to the timing and result of the ACIP vote on a universal hepatitis b recommendation.
- Risks that collaborators will not get approval of their vaccine candidates.
- Risks related to the development and pre-clinical and clinical testing of vaccines containing CpG 1018.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...